Ambrose acquires AM-Pharma for rare disease pipeline

Ambrose Healthcare has acquired Dutch biotech AM-Pharma for up to €161 million, according to European Biotechnology. The transaction brings an enzyme replacement therapy into the British rare disease specialist’s pipeline.

European Biotechnology also reported that the acquisition adds AM-Pharma’s development base in Utrecht to Ambrose Healthcare. The deal connects a British rare disease specialist with a Dutch biotech company and its Utrecht development operations.

Pipeline addition reported

European Biotechnology characterized the acquisition as an expansion of Ambrose Healthcare’s rare disease pipeline. The reported addition is an enzyme replacement therapy.

For pharmaceutical and biotech sales professionals following rare disease organizations, the transaction is a portfolio event involving Ambrose Healthcare and AM-Pharma. European Biotechnology’s report identifies the therapy addition and the development base as the two stated elements joining Ambrose through the acquisition.

The reported transaction value is up to €161 million. European Biotechnology identified Ambrose Healthcare as the acquirer and AM-Pharma as the acquired Dutch biotech.

Utrecht development base joins Ambrose

Alongside the enzyme replacement therapy, AM-Pharma contributes a development base in Utrecht, European Biotechnology reported. Utrecht is the development location named in the report.

The acquisition places the therapy and development base within Ambrose Healthcare’s organization, according to European Biotechnology. The publisher described Ambrose as a British rare disease specialist and AM-Pharma as a Dutch biotech.

Transaction details

• Acquirer: Ambrose Healthcare
• Acquired company: AM-Pharma
• Reported value: up to €161 million
• Pipeline addition: an enzyme replacement therapy
• Development base: Utrecht

European Biotechnology reported the deal as an acquisition that expands Ambrose Healthcare’s rare disease pipeline while adding the Utrecht development base from AM-Pharma.

Sales professionals can track the reported acquisition as a change in the organizations and assets identified by European Biotechnology: Ambrose Healthcare, AM-Pharma, an enzyme replacement therapy, and the Utrecht development base.